Clearstead Advisors’s Abivax ABVX Stock Holding History

Clearstead Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,026	Closed	-$138K	–	2241
2025 Q4	$138K	Buy	+1,026	New	+$112K	﹤0.01%	1026

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Clearstead Advisors's ABVX Position: Q1 2026 in Review

Clearstead Advisors sold out of Abivax (ABVX) in Q1 2026, closing a stake of 1,026 shares — an estimated $138K sold.

Clearstead Advisors first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $138K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

Clearstead Advisors reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
Clearstead Advisors sold 1,026 Abivax shares in Q1 2026, an estimated $138K.
Clearstead Advisors first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
Clearstead Advisors's Abivax position peaked at $138K in Q4 2025.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.